Shalby LtdQ1 FY27
Shalby Ltd Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹154P/E: 42.0Market Cap: ₹1.7K CrSector: Healthcare Services
Management growth scorecard
Revenue
Category 3
Margin
Category 1
Fundraise
Yes
Order
N/A
Capex
Yes
3 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 3- →Shalby MedTech showed strong revenue growth: ₹47 crores in Q1 FY27, a 53% YoY increase.
- →India operations grew 98% YoY, showing increasing product demand and improving execution.
- →US business sales remained stable with modest 9% YoY growth; multiple initiatives in progress to boost US sales.
- →MedTech business aims to sustain strong growth momentum with a maintained CAGR of 93%.
- →Hospital segment occupancy improved, with a 9.8% YoY increase in occupied beds and expected EBITDA margin rise to ~20%.
- →Gurgaon unit achieved EBITDA breakeven, with further occupancy growth expected.
- →New specialties and doctor recruitment underway to drive further hospital revenue growth.
- →Overall, management is confident of improving profitability and revenue growth across segments in coming quarters.
Margin guidance
Category 1- →Shalby expects improved profitability and operating leverage across its portfolio, aiming for sustained growth in earnings.
- →Hospital segment margins are anticipated to improve, targeting an EBITDA margin upward of 20% for FY27.
- →The Gurgaon unit has achieved EBITDA break-even and is expected to sustain and grow profitability in coming quarters.
- →MedTech business shows strong revenue growth (53% YoY) with EBITDA turning positive for four consecutive quarters, signaling improving operating earnings.
- →Internal initiatives are driving cost reductions (e.g., ₹3 crores per month reduction in cash flow requirement in MedTech).
- →Consolidated PAT improved to ₹10.5 crores in Q1 FY27, up from ₹7.7 crores YoY, indicating strong growth in net profits.
- →ROCE is currently around 7% consolidated, expected to improve to industry standards (11%-13%) within 1-2 years.
- →Management projects stable or reducing net debt, supporting future earnings growth without increased financial burden.
Fundraise plans
Yes- →No new fresh debt infusion is planned currently.
- →Recent ₹129 crores working capital facility from Kotak is a replacement of existing debt at a better cost (30 basis points lower), not an increase.
- →Net debt levels are stable or expected to reduce in coming quarters, with no increase anticipated.
- →For the planned Mumbai greenfield hospital expansion (200 beds at Asha Parekh Hospital), cash CAPEX outlay and funding approach will be assessed upon finalization.
- →Management indicated possible use of internal accruals or debt but no definitive fundraising decision yet.
- →No further debt infusion is expected into the Gurgaon hospital or MedTech units.
- →Overall, debt profile is being managed with focus on efficient cost and stable or reducing net debt.
Order book
The transcript does not explicitly mention the current or expected order book or pending orders for Shalby Limited. However, relevant points that indicate business momentum and future growth include:
- Strong consolidated revenue growth of 11.6% YoY reaching ₹338.6 crores in Q1 FY27.
- MedTech business revenue grew about 53% YoY.
- Significant growth in occupancy and revenue in hospital units such as Krishna, Mohali, and Naroda (approx. 30% YoY growth).
- Ongoing initiatives including new doctor recruitment, specialties deployment likely to boost revenue further.
- Discussions and plans underway for Mumbai expansion with 200-bed Asha Parekh Hospital development.
- Active efforts to improve government scheme renewals and TPA tie-ups which could increase volumes.
- The company is focused on selective investments in products and technology for sustainable long-term growth.
No specific order book or pending orders value has been disclosed in the transcript.
Capex plans
Yes- **Mumbai Expansion (Asha Parekh Hospital, 200 beds):** Planned as a greenfield project with cash CAPEX outlay expected around April 2027. Investment benchmarks and funding sources (debt vs internal accruals) will be assessed once finalized. No additional debt infusion anticipated for existing hospitals or MedTech for now.
- **MedTech Business:** Continuing selective investments in products and technologies for sustainable long-term growth; recent CAPEX already deployed, including bunker facility and robotics. Minimal CAPEX planned going forward.
- **Operational Efficiencies:** Initiatives underway to reduce cash flow requirements by ~₹3 crores per month through operational improvements and vendor partnerships in MedTech.
- **Working Capital & Inventory Optimization:** Ongoing focus on inventory optimization and cash conversion cycle improvements with automated tools and stronger follow-ups.
Overall, strategic investments are focused on capacity expansion in Mumbai and enhancing MedTech capabilities with a disciplined CAPEX approach.
Track Shalby Ltd — get its next earnings analysis in your feed
Margin guidance
Category 1- →Shalby expects improved profitability and operating leverage across its portfolio, aiming for sustained growth in earnings.
- →Hospital segment margins are anticipated to improve, targeting an EBITDA margin upward of 20% for FY27.
- →The Gurgaon unit has achieved EBITDA break-even and is expected to sustain and grow profitability in coming quarters.
- →MedTech business shows strong revenue growth (53% YoY) with EBITDA turning positive for four consecutive quarters, signaling improving operating earnings.
- →Internal initiatives are driving cost reductions (e.g., ₹3 crores per month reduction in cash flow requirement in MedTech).
- →Consolidated PAT improved to ₹10.5 crores in Q1 FY27, up from ₹7.7 crores YoY, indicating strong growth in net profits.
- →ROCE is currently around 7% consolidated, expected to improve to industry standards (11%-13%) within 1-2 years.
- →Management projects stable or reducing net debt, supporting future earnings growth without increased financial burden.
Order book
The transcript does not explicitly mention the current or expected order book or pending orders for Shalby Limited. However, relevant points that indicate business momentum and future growth include:
- Strong consolidated revenue growth of 11.6% YoY reaching ₹338.6 crores in Q1 FY27.
- MedTech business revenue grew about 53% YoY.
- Significant growth in occupancy and revenue in hospital units such as Krishna, Mohali, and Naroda (approx. 30% YoY growth).
- Ongoing initiatives including new doctor recruitment, specialties deployment likely to boost revenue further.
- Discussions and plans underway for Mumbai expansion with 200-bed Asha Parekh Hospital development.
- Active efforts to improve government scheme renewals and TPA tie-ups which could increase volumes.
- The company is focused on selective investments in products and technology for sustainable long-term growth.
No specific order book or pending orders value has been disclosed in the transcript.
How does Shalby Ltd rank vs peers in Healthcare Services?
Pro feature1Shalby Ltd
Rev 3Mar 1
See full Healthcare Services sector rankings
How does Shalby Ltd rank in Healthcare Services?
Compare Shalby Ltd against every Healthcare Services company (Q1 FY27) on revenue, margins and earnings-call signals.